{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T03:10:56Z","timestamp":1788577856393,"version":"build-2803163510"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>MicroRNA (miRNA) expression is known to be deregulated in ovarian carcinomas. However, limited data is available about the miRNA expression pattern for the benign or borderline ovarian tumors as well as differential miRNA expression pattern associated with histological types, grades or clinical stages in ovarian carcinomas. We defined patterns of microRNA expression in tissues from normal, benign, borderline, and malignant ovarian tumors and explored the relationship between frequently deregulated miRNAs and clinicopathologic findings, response to therapy, survival, and association with Her-2\/neu status in ovarian carcinomas.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We measured the expression of nine miRNAs (miR-181d, miR-30a-3p, miR-30c, miR-30d, miR-30e-3p, miR-368, miR-370, miR-493-5p, miR-532-5p) in 171 formalin-fixed, paraffin-embedded ovarian tissue blocks as well as six normal human ovarian surface epithelial (HOSE) cell lines using Taqman-based real-time PCR assays. Her-2\/neu overexpression was assessed in ovarian carcinomas (n\u2009=\u2009109 cases) by immunohistochemistry analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Expression of four miRNAs (miR-30c, miR-30d, miR-30e-3p, miR-370) was significantly different between carcinomas and benign ovarian tissues as well as between carcinoma and borderline tissues. An additional three miRNAs (miR-181d, miR-30a-3p, miR-532-5p) were significantly different between borderline and carcinoma tissues. Expression of miR-532-5p was significantly lower in borderline than in benign tissues. Among ovarian carcinomas, expression of four miRNAs (miR-30a-3p, miR-30c, miR-30d, miR-30e-3p) was lowest in mucinous and highest in clear cell samples. Expression of miR-30a-3p was higher in well-differentiated compared to poorly differentiated tumors (<jats:italic>P<\/jats:italic>\u2009=\u20090.02), and expression of miR-370 was higher in stage I\/II compared to stage III\/IV samples (<jats:italic>P<\/jats:italic>\u2009=\u20090.03). In multivariate analyses, higher expression of miR-181d, miR-30c, miR-30d, and miR-30e-3p was associated with significantly better disease-free or overall survival. Finally, lower expression of miR-30c, miR-30d, miR-30e-3p and miR-532-5p was significantly associated with overexpression of Her-2\/neu.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Aberrant expression of miRNAs is common in ovarian tumor suggesting involvement of miRNA in ovarian tumorigenesis. They are associated with histology, clinical stage, survival and oncogene expression in ovarian carcinoma.<\/jats:p><\/jats:sec>","DOI":"10.1186\/1477-7819-10-174","type":"journal-article","created":{"date-parts":[[2012,8,28]],"date-time":"2012-08-28T00:14:15Z","timestamp":1346112855000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":84,"title":["MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features"],"prefix":"10.1186","volume":"10","author":[{"given":"Heejeong","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chul Soo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Deftereos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice","family":"Morihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua E","family":"Stern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen E","family":"Hawes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Swisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy B","family":"Kiviat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghua","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,8,27]]},"reference":[{"key":"1049_CR1","doi-asserted-by":"publisher","first-page":"122","DOI":"10.4143\/crt.2009.41.3.122","volume":"41","author":"YJ Won","year":"2009","unstructured":"Won YJ, Sung J, Jung KW, Kong HJ, Park S, Shin HR, Park EC, Ahn YO, Hwang IK, Lee DH, Choi JS, Kim WC, Lee TY, Yoo CI, Bae JM, Kim ON, Chung W, Kong IS, Lee DH, Lee JS: Nationwide cancer incidence in Korea, 2003-2005. Cancer Res Treat. 2009, 41: 122-131. 10.4143\/crt.2009.41.3.122.","journal-title":"Cancer Res Treat"},{"key":"1049_CR2","doi-asserted-by":"crossref","first-page":"795","DOI":"10.6004\/jnccn.2008.0059","volume":"6","author":"CM Coticchia","year":"2008","unstructured":"Coticchia CM, Yang J, Moses MA: Ovarian cancer biomarkers: current options and future promise. J Natl Compr Canc Netw. 2008, 6: 795-802.","journal-title":"J Natl Compr Canc Netw"},{"key":"1049_CR3","first-page":"805","volume-title":"Blaustein\u2019s pathology of the female genital tract","author":"RJ Kurman","year":"2002","unstructured":"Kurman RJ: Blaustein\u2019s pathology of the female genital tract. Edited by: Kurman RJ. 2002, New York: Springer-Verlag, 805-5","edition":"5"},{"key":"1049_CR4","doi-asserted-by":"publisher","first-page":"728","DOI":"10.2353\/ajpath.2007.070070","volume":"171","author":"W Zhang","year":"2007","unstructured":"Zhang W, Dahlberg JE, Tam W: MicroRNAs in tumorigenesis: a primer. Am J Pathol. 2007, 171: 728-738. 10.2353\/ajpath.2007.070070.","journal-title":"Am J Pathol"},{"key":"1049_CR5","first-page":"1161","volume":"23","author":"DC Corney","year":"2008","unstructured":"Corney DC, Nikitin AY: MicroRNA and ovarian cancer. Histol Histopathol. 2008, 23: 1161-1169.","journal-title":"Histol Histopathol"},{"key":"1049_CR6","doi-asserted-by":"publisher","first-page":"7004","DOI":"10.1073\/pnas.0801615105","volume":"105","author":"L Zhang","year":"2008","unstructured":"Zhang L, Volinia S, Bonome T, Calin GA, Greshock J, Yang N, Liu CG, Giannakakis A, Alexiou P, Hasegawa K, Johnstone CN, Megraw MS, Adams S, Lassus H, Huang J, Kaur S, Liang S, Sethupathy P, Leminen A, Simossis VA, Sandaltzopoulos R, Naomoto Y, Katsaros D, Gimotty PA, DeMichele A, Huang Q, B\u00fctzow R, Rustgi AK, Weber BL, Birrer MJ: Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci USA. 2008, 105: 7004-7009. 10.1073\/pnas.0801615105.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1049_CR7","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/modpathol.2008.33","volume":"21","author":"RJ Flavin","year":"2008","unstructured":"Flavin RJ, Smyth PC, Finn SP, Laios A, O'Toole SA, Barrett C, Ring M, Denning KM, Li J, Aherne ST, Aziz NA, Alhadi A, Sheppard BL, Loda M, Martin C, Sheils OM, O'Leary JJ: Altered eIF6 and Dicer expression is associated with clinicopathological features in ovarian serous carcinoma patients. Mod Pathol. 2008, 21: 676-684. 10.1038\/modpathol.2008.33.","journal-title":"Mod Pathol"},{"key":"1049_CR8","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1517\/14712598.7.9.1375","volume":"7","author":"A Giannakakis","year":"2007","unstructured":"Giannakakis A, Coukos G, Hatzigeorgiou A, Sandaltzopoulos R, Zhang L: miRNA genetic alterations in human cancers. Expert Opin Biol Ther. 2007, 7: 1375-1386. 10.1517\/14712598.7.9.1375.","journal-title":"Expert Opin Biol Ther"},{"key":"1049_CR9","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1002\/ijc.23325","volume":"122","author":"N Yang","year":"2008","unstructured":"Yang N, Coukos G, Zhang L: MicroRNA epigenetic alterations in human cancer: one step forward in diagnosis and treatment. Int J Cancer. 2008, 122: 963-968.","journal-title":"Int J Cancer"},{"key":"1049_CR10","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1056\/NEJMe0808667","volume":"359","author":"FJ Slack","year":"2008","unstructured":"Slack FJ, Weidhaas JB: MicroRNA in cancer prognosis. N Engl J Med. 2008, 359: 2720-2722. 10.1056\/NEJMe0808667.","journal-title":"N Engl J Med"},{"key":"1049_CR11","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1093\/jnci\/djp172","volume":"101","author":"K Hede","year":"2009","unstructured":"Hede K: Small RNAs are raising big expectations. J Natl Cancer Inst. 2009, 101: 840-841. 10.1093\/jnci\/djp172.","journal-title":"J Natl Cancer Inst"},{"key":"1049_CR12","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.4161\/cc.7.17.6597","volume":"7","author":"S Deng","year":"2008","unstructured":"Deng S, Calin GA, Croce CM, Coukos G, Zhang L: Mechanisms of microRNA deregulation in human cancer. Cell Cycle. 2008, 7: 2643-2646. 10.4161\/cc.7.17.6597.","journal-title":"Cell Cycle"},{"key":"1049_CR13","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ygyno.2008.08.036","volume":"112","author":"KE Resnick","year":"2009","unstructured":"Resnick KE, Alder H, Hagan JP, Richardson DL, Croce CM, Cohn DE: The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol. 2009, 112: 55-59. 10.1016\/j.ygyno.2008.08.036.","journal-title":"Gynecol Oncol"},{"key":"1049_CR14","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ccr.2007.12.008","volume":"13","author":"SL Yu","year":"2008","unstructured":"Yu SL, Chen HY, Chang GC, Chen CY, Chen HW, Singh S, Cheng CL, Yu CJ, Lee YC, Chen HS, Su TJ, Chiang CC, Li HN, Hong QS, Su HY, Chen CC, Chen WJ, Liu CC, Chan WK, Chen WJ, Li KC, Chen JJ, Yang PC: MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell. 2008, 13: 48-57. 10.1016\/j.ccr.2007.12.008.","journal-title":"Cancer Cell"},{"key":"1049_CR15","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1757-2215-2-19","volume":"2","author":"MF Gallagher","year":"2009","unstructured":"Gallagher MF, Flavin RJ, Elbaruni SA, McInerney JK, Smyth PC, Salley YM, Vencken SF, O'Toole SA, Laios A, Lee MY, Denning K, Li J, Aherne ST, Lao KQ, Martin CM, Sheils OM, O'Leary JJ: Regulation of microRNA biosynthesis and expression in 2102Ep embryonal carcinoma stem cells is mirrored in ovarian serous adenocarcinoma patients. J Ovarian Res. 2009, 2: 19-10.1186\/1757-2215-2-19.","journal-title":"J Ovarian Res"},{"key":"1049_CR16","doi-asserted-by":"publisher","first-page":"8699","DOI":"10.1158\/0008-5472.CAN-07-1936","volume":"67","author":"MV Iorio","year":"2007","unstructured":"Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, Calin GA, M\u00e9nard S, Croce CM: MicroRNA signatures in human ovarian cancer. Cancer Res. 2007, 67: 8699-8707. 10.1158\/0008-5472.CAN-07-1936.","journal-title":"Cancer Res"},{"key":"1049_CR17","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1158\/0008-5472.CAN-07-2488","volume":"68","author":"H Yang","year":"2008","unstructured":"Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV, Cheng JQ: MicroRNA expression profiling inhuman ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 2008, 68: 425-433. 10.1158\/0008-5472.CAN-07-2488.","journal-title":"Cancer Res"},{"key":"1049_CR18","doi-asserted-by":"publisher","first-page":"e2436","DOI":"10.1371\/journal.pone.0002436","volume":"3","author":"N Dahiya","year":"2008","unstructured":"Dahiya N, Sherman-Baust CA, Wang TL, Davidson B, Shih IM, Zhang Y, Wood W, Becker KG, Morin PJ: MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS One. 2008, 3: e2436-10.1371\/journal.pone.0002436.","journal-title":"PLoS One"},{"key":"1049_CR19","doi-asserted-by":"publisher","first-page":"e5311","DOI":"10.1371\/journal.pone.0005311","volume":"4","author":"SK Wyman","year":"2009","unstructured":"Wyman SK, Parkin RK, Mitchell PS, Fritz BR, O'Briant K, Godwin AK, Urban N, Drescher CW, Knudsen BS, Tewari M: Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries. PLoS One. 2009, 4: e5311-10.1371\/journal.pone.0005311.","journal-title":"PLoS One"},{"key":"1049_CR20","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1158\/1078-0432.CCR-07-1731","volume":"14","author":"EJ Nam","year":"2008","unstructured":"Nam EJ, Yoon H, Kim SW, Kim H, Kim YT, Kim JH, Kim JW, Kim S: MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res. 2008, 14: 2690-2695. 10.1158\/1078-0432.CCR-07-1731.","journal-title":"Clin Cancer Res"},{"key":"1049_CR21","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ygyno.2009.04.024","volume":"114","author":"R Eitan","year":"2009","unstructured":"Eitan R, Kushnir M, Lithwick-Yanai G, David MB, Hoshen M, Glezerman M, Hod M, Sabah G, Rosenwald S, Levavi H: Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients. Gynecol Oncol. 2009, 114: 253-259. 10.1016\/j.ygyno.2009.04.024.","journal-title":"Gynecol Oncol"},{"key":"1049_CR22","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ygyno.2009.01.014","volume":"113","author":"T Boren","year":"2009","unstructured":"Boren T, Xiong Y, Hakam A, Wenham R, Apte S, Chan G, Kamath SG, Chen DT, Dressman H, Lancaster JM: MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol. 2009, 113: 249-255. 10.1016\/j.ygyno.2009.01.014.","journal-title":"Gynecol Oncol"},{"key":"1049_CR23","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.ygyno.2008.08.017","volume":"111","author":"A Sorrentino","year":"2008","unstructured":"Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G, Ferlini C: Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol. 2008, 111: 478-486. 10.1016\/j.ygyno.2008.08.017.","journal-title":"Gynecol Oncol"},{"key":"1049_CR24","doi-asserted-by":"publisher","first-page":"10307","DOI":"10.1158\/0008-5472.CAN-08-1954","volume":"68","author":"N Yang","year":"2008","unstructured":"Yang N, Kaur S, Volinia S, Greshock J, Lassus H, Hasegawa K, Liang S, Leminen A, Deng S, Smith L, Johnstone CN, Chen XM, Liu CG, Huang Q, Katsaros D, Calin GA, Weber BL, B\u00fctzow R, Croce CM, Coukos G, Zhang L: MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res. 2008, 68: 10307-10314. 10.1158\/0008-5472.CAN-08-1954.","journal-title":"Cancer Res"},{"key":"1049_CR25","doi-asserted-by":"publisher","first-page":"e7314","DOI":"10.1371\/journal.pone.0007314","volume":"4","author":"CH Lee","year":"2009","unstructured":"Lee CH, Subramanian S, Beck AH, Espinosa I, Senz J, Zhu SX, Huntsman D, van de Rijn M, Gilks CB: MicroRNA profiling of BRCA1\/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary. PLoS One. 2009, 4: e7314-10.1371\/journal.pone.0007314.","journal-title":"PLoS One"},{"key":"1049_CR26","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1476-4598-7-35","volume":"7","author":"A Laios","year":"2008","unstructured":"Laios A, O'Toole S, Flavin R, Martin C, Kelly L, Ring M, Finn SP, Barrett C, Loda M, Gleeson N, D'Arcy T, McGuinness E, Sheils O, Sheppard B, O' Leary J: Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Mol Cancer. 2008, 7: 35-10.1186\/1476-4598-7-35.","journal-title":"Mol Cancer"},{"key":"1049_CR27","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.biocel.2010.01.014","volume":"42","author":"MTM van Jaarsveld","year":"2010","unstructured":"van Jaarsveld MTM, Jozien H, Els MJJB, Erik ACW: MicroRNAs in ovarian cancer biology and therapy resistance. Int J Biochem Cell Biol. 2010, 42: 1282-1290. 10.1016\/j.biocel.2010.01.014.","journal-title":"Int J Biochem Cell Biol"},{"key":"1049_CR28","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.ygyno.2008.07.036","volume":"111","author":"Q Feng","year":"2008","unstructured":"Feng Q, Deftereos G, Hawes SE, Stern JE, Willner JB, Swisher EM, Xi L, Drescher C, Urban N, Kiviat N: DNA hypermethylation, Her-2\/neu overexpression and p53 mutations in ovarian carcinoma. Gynecol Oncol. 2008, 111: 320-329. 10.1016\/j.ygyno.2008.07.036.","journal-title":"Gynecol Oncol"},{"key":"1049_CR29","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1200\/JCO.2006.09.2775","volume":"25","author":"AC Wolff","year":"2007","unstructured":"Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF: American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007, 25: 118-145.","journal-title":"J Clin Oncol"},{"key":"1049_CR30","doi-asserted-by":"publisher","first-page":"R27","DOI":"10.1186\/bcr2257","volume":"11","author":"AJ Lowery","year":"2009","unstructured":"Lowery AJ, Miller N, Devaney A, McNeill RE, Davoren PA, Lemetre C, Benes V, Schmidt S, Blake J, Ball G, Kerin MJ: MicroRNA signatures predict oestrogen receptor, progesterone receptor and Her2\/neu receptor status in breast cancer. Breast Cancer Res. 2009, 11: R27-10.1186\/bcr2257.","journal-title":"Breast Cancer Res"},{"key":"1049_CR31","doi-asserted-by":"publisher","first-page":"18515","DOI":"10.1074\/jbc.M109.006676","volume":"284","author":"TH Huang","year":"2009","unstructured":"Huang TH, Wu F, Loeb GB, Hsu R, Heidersbach A, Brincat A, Horiuchi D, Lebbink RJ, Mo YY, Goga A, McManus MT: Up-regulation of miR-21 by Her2\/neu signaling promotes cell invasion. J Biol Chem. 2009, 284: 18515-18524. 10.1074\/jbc.M109.006676.","journal-title":"J Biol Chem"},{"key":"1049_CR32","doi-asserted-by":"publisher","first-page":"29897","DOI":"10.1074\/jbc.M804612200","volume":"283","author":"TE Miller","year":"2008","unstructured":"Miller TE, Ghoshal K, Ramaswamy B, Roy S, Datta J, Shapiro CL, Jacob S, Majumder S: MicroRNA-221\/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem. 2008, 283: 29897-29903. 10.1074\/jbc.M804612200.","journal-title":"J Biol Chem"},{"key":"1049_CR33","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1111\/j.1349-7006.2002.tb01231.x","volume":"93","author":"M Fujimura","year":"2002","unstructured":"Fujimura M, Katsumata N, Tsuda H, Uchi N, Miyazaki S, Hidaka T, Sakai M, Saito S: HER2 is frequently over-expressed in ovarian clear cell adenocarcinoma: possible novel treatment modality using recombinant monoclonal antibody against HER2, trastuzumab. Jpn J Cancer Res. 2002, 93: 1250-1257. 10.1111\/j.1349-7006.2002.tb01231.x.","journal-title":"Jpn J Cancer Res"},{"key":"1049_CR34","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/IGC.0b013e3181a48cf9","volume":"19","author":"R Flavin","year":"2009","unstructured":"Flavin R, Smyth P, Barrett C, Russell S, Wen H, Wei J, Laios A, O'Toole S, Ring M, Denning K, Li J, Aherne S, Sammarae D, Aziz NA, Alhadi A, Finn SP, Loda M, B S, Sheils O, O'Leary JJ: miR-29b expression is associated with disease-free survival in patients with ovarian serous carcinoma. Int J Gynecol Cancer. 2009, 19: 641-647. 10.1111\/IGC.0b013e3181a48cf9.","journal-title":"Int J Gynecol Cancer"},{"key":"1049_CR35","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.ygyno.2011.01.025","volume":"121","author":"KK Shih","year":"2011","unstructured":"Shih KK, Qin LX, Tanner EJ, Zhou Q, Bisogna M, Dao F, Olvera N, Viale A, Barakat RR, Levine DA: A microRNA survival signature (MiSS) for advanced ovarian cancer. Gynecol Oncol. 2011, 121: 444-450. 10.1016\/j.ygyno.2011.01.025.","journal-title":"Gynecol Oncol"},{"key":"1049_CR36","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.ygyno.2009.05.022","volume":"114","author":"X Hu","year":"2009","unstructured":"Hu X, Macdonald DM, Huettner PC, Feng Z, El Naqa IM, Schwarz JK, Mutch DG, Grigsby PW, Powell SN, Wang X: A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. Gynecol Oncol. 2009, 114: 457-464. 10.1016\/j.ygyno.2009.05.022.","journal-title":"Gynecol Oncol"},{"key":"1049_CR37","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1677\/ERC-10-0148","volume":"18","author":"S Leskel\u00e4","year":"2010","unstructured":"Leskel\u00e4 S, Leandro-Garc\u00eda LJ, Mendiola M, Barriuso J, Inglada-P\u00e9rez L, Mu\u00f1oz I, Mart\u00ednez-Delgado B, Redondo A, de Santiago J, Robledo M, Hardisson D, Rodr\u00edguez-Antona C: The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients. Endocr Relat Cancer. 2010, 18: 85-95. 10.1677\/ERC-10-0148.","journal-title":"Endocr Relat Cancer"},{"key":"1049_CR38","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/gcc.20768","volume":"49","author":"K Wurz","year":"2010","unstructured":"Wurz K, Garcia RL, Goff BA, Mitchell PS, Lee JH, Tewari M, Swisher EM: MiR-221 and MiR-222 alterations in sporadic ovarian carcinoma: Relationship to CDKN1B, CDKNIC and overall survival. Genes Chromosomes Cancer. 2010, 49: 577-584.","journal-title":"Genes Chromosomes Cancer"},{"key":"1049_CR39","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S1470-2045(11)70012-2","volume":"12","author":"S Marchini","year":"2011","unstructured":"Marchini S, Cavalieri D, Fruscio R, Calura E, Garavaglia D, Nerini IF, Mangioni C, Cattoretti G, Clivio L, Beltrame L, Katsaros D, Scarampi L, Menato G, Perego P, Chiorino G, Buda A, Romualdi C, D'Incalci M: Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections. Lancet Oncol. 2011, 12: 273-285. 10.1016\/S1470-2045(11)70012-2.","journal-title":"Lancet Oncol"},{"key":"1049_CR40","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s00345-010-0633-4","volume":"29","author":"J Heinzelmann","year":"2011","unstructured":"Heinzelmann J, Henning B, Sanjmyatav J, Posorski N, Steiner T, Wunderlich H, Gajda MR, Junker K: Specific miRNA signatures are associated with metastasis and poor prognosis in clear cell renal cell carcinoma. World J Urol. 2011, 29: 367-373. 10.1007\/s00345-010-0633-4.","journal-title":"World J Urol"},{"key":"1049_CR41","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s10549-010-0940-x","volume":"127","author":"FG Rodr\u00edguez-Gonz\u00e1lez","year":"2011","unstructured":"Rodr\u00edguez-Gonz\u00e1lez FG, Sieuwerts AM, Smid M, Look MP, Meijer-van Gelder ME, de Weerd V, Sleijfer S, Martens JW, Foekens JA: MicroRNA-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer. Breast Cancer Res Treat. 2011, 127: 43-51. 10.1007\/s10549-010-0940-x.","journal-title":"Breast Cancer Res Treat"},{"key":"1049_CR42","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1165\/rcmb.2009-0060OC","volume":"42","author":"S Busacca","year":"2010","unstructured":"Busacca S, Germano S, De Cecco L, Rinaldi M, Comoglio F, Favero F, Murer B, Mutti L, Pierotti M, Gaudino G: MicroRNA s signature of malignant mesothelioma with potential diagnostic and prognostic implications. Am J Respir Cell Mol Biol. 2010, 42: 312-319. 10.1165\/rcmb.2009-0060OC.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"1049_CR43","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1183\/09031936.00029610","volume":"37","author":"J Silva","year":"2011","unstructured":"Silva J, Garc\u00eda V, Zaballos \u00c1, Provencio M, Lombard\u00eda L, Almonacid L, Garc\u00eda JM, Dom\u00ednguez G, Pe\u00f1a C, Diaz R, Herrera M, Varela A, Bonilla F: Vesicle-related microRNAs in plasma of nonsmall cell lung cancer patients and correlation with survival. Eur Respir J. 2011, 37: 617-623. 10.1183\/09031936.00029610.","journal-title":"Eur Respir J"},{"key":"1049_CR44","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ccr.2011.05.027","volume":"20","author":"A Gaziel-Sovran","year":"2011","unstructured":"Gaziel-Sovran A, Segura MF, Di Micco R, Collins MK, Hanniford D, de Vega-Saenz Miera E, Rakus JF, Dankert JF, Shang S, Kerbel RS, Bhardwaj N, Shao Y, Darvishian F, Zavadil J, Erlebacher A, Mahal LK, Osman I, Hernando E: miR-30b\/30d regulation of GalNActransferases enhances invasion and immunosuppression during metastasis. Cancer Cell. 2011, 20: 104-118. 10.1016\/j.ccr.2011.05.027.","journal-title":"Cancer Cell"},{"key":"1049_CR45","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1200\/JCO.2009.24.9342","volume":"28","author":"Z Hu","year":"2010","unstructured":"Hu Z, Chen X, Zhao Y, Tian T, Jin G, Shu Y, Chen Y, Xu L, Zen K, Zhang C, Shen H: Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol. 2010, 28: 1721-1726. 10.1200\/JCO.2009.24.9342.","journal-title":"J Clin Oncol"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1477-7819-10-174.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,28]],"date-time":"2024-04-28T19:13:39Z","timestamp":1714331619000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/1477-7819-10-174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,27]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["1049"],"URL":"https:\/\/doi.org\/10.1186\/1477-7819-10-174","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,27]]},"assertion":[{"value":"9 May 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"174"}}